jeudi 6 juin 2019

Onco Actu du 6 juin 2019


4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice? [Mayo Clinic]










4.16 DÉP., DIAG. & PRONO. - PANCRÉAS



Biomarker predicts which pancreatic cysts may become cancerous [WUSTL]











Diagnostic Power of Pancreatic Cancer Blood Test Gets a Boost From Methylated DNA Markers [Genome Web]











4.9 DÉP., DIAG. & PRONO. - SEIN



Researchers Study Surveillance MRI in Breast Cancer Survivors [RSNA]











5.10 TRAITEMENTS - ESSAIS



Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia [AstraZeneca]











5.12 IMMUNOTHÉRAPIES



UT Southwestern develops test to predict immunotherapy response in kidney cancer [UT Southwestern]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Killer T cells that amplify immune response to viral infections may be a key to better cancer drugs [Scripps]











5.2 PHARMA



Bristol-Myers bumps CSO Lynch, brings on Novartis and Celgene vets to drive new launches [Fierce Pharma]











Bristol-Myers bumps off chief scientist in another big shakeup, bringing in Celgene and Novartis execs [EndPoints]











Pfizer scoops Calico exec Jeff Settleman to head big oncology R&D ops in La Jolla [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Move aside, Humira. Merck's Keytruda will capture industry's top sales spot in 2024: report [Fierce Pharma]











Biotechs dive deeper into targeted cancer research, despite costs [Biopharma Dive]











China’s Churning Out Revolutionary Cancer Drugs Much Cheaper Than the U.S. [Bloomberg]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA's Woodcock defends accelerated approvals and talks of culture shift in clinical trials [Biopharma Dive]











FDA 'open for business' in considering real-world evidence, Sharpless says [Biopharma Dive]










Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies [The Oncologist]











5.4 TRAITEMENTS - ECONOMIE



Ned Sharpless weighs in on gene therapy pricing debate, suggesting 'the messaging got lost' [EndPoints]











5.5.1 ASCO (GÉNÉRAL)



3 takeaways from cancer's biggest conference [Biopharma Dive]











ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More [Xconomy]











5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS



ASCO or AdCo? Advertising splashes all over meeting, but attendees mostly blasé [Fierce Pharma]











Was ASCO 2019 'quiet'? Pharma, biotech execs weigh in [Fierce Pharma]










MacroGenics dives as breast cancer drug shows small improvement [Biopharma Dive]











5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)



Outlining the Risks That Go Along With the Benefit of CAR T-Cell Therapy [AJMC]











6. LUTTE CONTRE LES CANCERS



Will Europe's clampdown on faulty medical devices hurt patients? [Reuters]











6.10.1 POLITIQUES (USA)



Trump Administration Sharply Curtails Fetal Tissue Medical Research [NY Times]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



Katie Britton-Jordan: Sadly, vegan diets don’t cure cancer [Respectful Insolence]











6.6 PUBLICATIONS



Q&A: New Preprint Server for Clinical Research [The Scientist]










Medical preprint server debuts [Science]











New preprint server for medical research [BMJ]











6.7 DMP, BIG DATA & APPLIS



Pilot Projects to Assess Newly Released mCODE Proposals for Cancer-Related EHR Standardization [Genome Web]











6.8 COMMUNICATION



Alex Trebek’s ‘near remission’ story serves as a reminder: Beware celebrity health news [HealthNewsReview]











6.9 CONTROVERSES



Congress Is Debating—Again—Whether Genes Can Be Patented [Wired]